Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lodz
Clinical trial register · Poland

Clinical Trials in Lodz, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC
2705
Studies in scope
all four open statuses
1389
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca80 Eli Lilly and Company24 Janssen Research & Development, LLC24 Novartis Pharmaceuticals21 Hoffmann-La Roche21
Site location
Warsaw1315 Krakow882 Poznan705 Gdansk657 Lodz619
All 264 locations
Target enrolment
to

Trials with a site in Lodz

619 of 2705 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Active, closed
Hoffmann-La Roche
Phase 3
751
Bydgoszcz, Gdansk, Kielce, Krakow, Lodz, Oświęcim, Plewiska, Poznan
2021-03-24
Recruiting
Bristol-Myers Squibb
Phase 3
153
Krakow, Lodz, Warsaw, Wroclaw
2021-03-23
Active, closed
Hoffmann-La Roche
Phase 3
746
?ory, Bydgoszcz, Katowice, Krosno, Lodz, Lublin, Warsaw, Zabrze
2021-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
700
Tarnów, Wroclaw, Dębica, Lodz
2021-03-15
Active, closed
Inossia AB
Not applicable
203
Lodz
2021-03-11
Active, closed
Celgene
Phase 3
313
Gdansk, Krakow, Lodz, Poznan, Wałbrzych, Wroclaw
2021-02-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Lodz, Lublin, Otwock, Rzeszów, Skorzewo, Torun, Warsaw
2021-02-23
Active, closed
AstraZeneca
Phase 1
155
Gdansk, Lodz, Lublin, Warsaw
2021-02-02
Active, closed
AstraZeneca
Phase 3
1,371
Gdynia, Konin, Koszalin, Lodz, Lublin, Olsztyn, Poznan
2021-01-28
Active, closed
Genmab
Phase 3
483
Gdansk, Katowice, Krakow, Lodz, Skorzewo, Wroclaw
2021-01-13
Active, closed
Galderma R&D
Phase 3
500
Bydgoszcz, Chorzów, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz
2021-01-11
Active, closed
AstraZeneca
Phase 1/2
245
Bydgoszcz, Koszalin, Lodz, Lublin
2020-12-28
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Lodz, Rzeszów, Warsaw
2020-12-11
Active, closed
GlaxoSmithKline
Phase 2/3
758
Bydgoszcz, Gdynia, Lodz, Olsztyn, Piła, Poznan
2020-12-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Poznan, Opole, Gdansk, Lodz, Warsaw
2020-12-04
Active, closed
Hoffmann-La Roche
Phase 3
769
Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Lublin, Oświęcim, Plewiska
2020-12-03
Active, closed
Hoffmann-La Roche
Phase 3
864
Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Późna, Rzeszów, Szczecin
2020-11-26
Active, closed
AstraZeneca
Phase 3
957
Bialystok, Gdansk, Krakow, Lodz, Poznan, Warsaw
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Bydgoszcz, Gdansk, Gdynia, Grzepnica, Lodz, Torun, Warsaw
2020-11-12
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 3
691
Bydgoszcz, Elblag, Gdansk, Gdynia, Kielce, Koszalin, Lodz, Radom
2020-11-12
Active, closed
Hoffmann-La Roche
Phase 3
985
Bydgoszcz, Katowice, Lodz, Późna, Rzeszów, Warsaw, Wroc?aw, Zabrze
2020-10-26
Active, closed
Bayer
Phase 3
402
Lodz, Lublin, Otwock, Siedlce, Warsaw
2020-10-20
Active, closed
Exelixis
Phase 3
575
Otwock, Bydgoszcz, Lodz, Poznan
2020-10-19
Active, closed
AstraZeneca
Phase 3
640
Katowice, Krakow, Lodz, Siedlce, Warsaw
2020-10-19
Active, closed
Acerta Pharma BV
Phase 3
611
Gdansk, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2020-10-08
Active, closed
GlaxoSmithKline
Phase 3
302
Bydgoszcz, Gdansk, Krakow, Lodz, Wroclaw
2020-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
696
Bydgoszcz, Gdynia, Konin, Krakow, Lodz, Lublin, Siedlce, Warsaw
2020-09-23
Active, closed
argenx
Phase 2
229
Krakow, Lodz, Lublin, Warsaw
2020-09-18
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Krakow, Wroclaw, Gdynia, Katowice, Lodz, Opole, Skorzewo, Warsaw
2020-09-16
Active, closed
AbbVie
Phase 3
531
Bydgoszcz, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-09-10
Active, closed
AbbVie
Phase 3
330
Piła, Poznan, Krakow, Lublin, Warsaw, Gdansk, Katowice, Lodz
2020-08-31
Recruiting
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
University of Siena
Observational
3,500
Lodz, Warsaw
2020-08-06
Active, closed
Incyte Corporation
Phase 2
112
Kracow, Lodz, Nowy Sącz, Wroclaw
2020-08-03
Active, closed
AstraZeneca
Phase 3
866
Bydgoszcz, Koszalin, Krakow, Lodz, Rzeszów, Warsaw, Wroclaw
2020-07-24
Active, closed
AstraZeneca
Phase 3
134
Chęciny, Gdansk, Lodz
2020-07-20
Active, closed
AstraZeneca
Phase 3
1,012
Bydgoszcz, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Rzeszów, Torun
2020-07-13
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Lodz, Zabrze
2020-07-07
Recruiting
BioInvent International AB
Phase 1/2
197
Gliwice, Katowice, Lodz
2020-06-29
Active, closed
Sanofi
Phase 3
337
Bydgoszcz, Lodz, Gdansk, Chorzów
2020-06-16
Active, closed
GlaxoSmithKline
Phase 1/2
106
Katowice, Lodz, Lublin
2020-06-08
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
Lublin, Lodz, Gdynia
2020-05-21
Active, closed
GlaxoSmithKline
Phase 3
494
Chorzów, Krakow, Lodz, Lublin, Nowy Sącz, Poznan, Warsaw
2020-05-07
Active, closed
AstraZeneca
Phase 3
805
Gdansk, Lodz, Lublin, Olsztyn
2020-05-05
Active, closed
AstraZeneca
Phase 2
240
Bydgoszcz, Lodz, Piła, Rzeszów, Skorzewo, Warsaw
2020-04-22
Active, closed
Eli Lilly and Company
Phase 3
58
Krakow, Lodz, Warsaw
2020-02-12
Active, closed
BeOne Medicines
Phase 3
955
Bialystok, Brzozów, Bydgoszcz, Chorzów, Gdansk, Gdask, Krakow, Lodz
2020-01-16
Active, closed
Sun Pharmaceutical Industries Limited
Phase 2/3
135
Bialystok, Katowice, Lodz, Lublin, Ostrowiec Świętokrzyski, Sosnowiec, Szczecin, Warsaw
2020-01-15
Active, closed
OncoVerity, Inc.
Phase 1
61
Krakow, Lodz, Warsaw
2019-12-23
Active, closed
Alnylam Pharmaceuticals
Phase 3
655
Wroclaw, Lodz, Warsaw, Gdansk, Katowice
2019-11-26
Active, closed
TG Therapeutics, Inc.
Phase 3
1,100
Katowice, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Zabrze
2019-11-18
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Warsaw, Gdansk, Gdynia, Lodz, Wroclaw
2019-11-13
Active, closed
GlaxoSmithKline
Phase 1/2
208
Gdansk, Katowice, Lodz, Lublin
2019-10-07
Active, closed
NeuroDerm Ltd.
Phase 3
381
Krakow, Lodz, Siemianowice Śląskie, Warsaw
2019-09-30
Active, closed
Applied Therapeutics, Inc.
Phase 3
675
Wroclaw, Bialystok, Krakow, Lodz, Poznan, Radom, Rzeszów
2019-09-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Gdansk, Krakow, Lodz, Poznan, Warsaw
2019-09-18
Active, closed
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
DrugXeomin
Merz Pharmaceuticals GmbH
Phase 3
603
Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw
2019-09-16
Active, closed
Pfizer
Phase 3
896
Poznan, Wroclaw, Będzin, Bialystok, Gdansk, Gdynia, Jelenia Góra, Lodz
2019-09-05
Recruiting
University Hospital Muenster
Phase 3
683
Bialystok, Bydgoszcz, Chorzów, Gdansk, Kielce, Krakow, Lodz, Lublin
2019-08-23
Active, closed
BeOne Medicines
Phase 3
510
Bydgoszcz, Chorzów, Gdansk, Gdask, Gdynia, Krakow, Legnica, Lodz
2019-08-20
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Bialystok, Gdansk, Katowice, Lodz, Opole, Warsaw
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Bydgoszcz, Olsztyn, Biała Podlaska, Gdansk, Krakow, Lodz, Lublin, Poznan
2019-08-09
Active, closed
Tesaro, Inc.
Phase 3
785
Bialystok, Gdynia, Lodz, Olsztyn, Poznan, Szczecin, Warsaw
2019-07-18
Recruiting
European Organisation for Research and Treatment of Cancer - EORTC
Observational
2,000
Lodz, Radom, Warsaw
2019-06-24
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Bialystok, Bydgoszcz, Chorzów, Gdansk, Katowice, Krakow, Lodz, Poznan
2019-05-08
Active, closed
AstraZeneca
Phase 3
810
Gdansk, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
2019-04-16
Recruiting
Eli Lilly and Company
Phase 3
190
Krakow, Lodz, Warsaw
2019-04-05
Recruiting
AstraZeneca
Phase 3
140
Bialystok, Krakow, Lodz, Warsaw
2019-04-02
Active, closed
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Częstochowa, Gdansk, Gdynia, Katowice, Lodz, Poznan, Skórzewo, Warsaw
2019-03-28
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Bialystok, Gdansk, Konin, Lodz, Olsztyn, Opole, Poznan, Tomaszów Mazowiecki
2019-03-21
Active, closed
AstraZeneca
Phase 3
724
Bydgoszcz, Elblag, Gdansk, Katowice, Lodz, Warsaw
2019-03-06
Active, closed
Acerta Pharma BV
Phase 3
984
Brzozów, Bydgoszcz, Gdynia, Krakow, Lodz, Lublin, Wroclaw
2019-02-25
Active, closed
AbbVie
Phase 1
364
Krakow, Warsaw, Lodz
2019-02-21
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Bydgoszcz, Gdansk, Gdynia, Lodz, Siedlce, Szczecin, Warsaw, Wroclaw
2019-01-25
Active, closed
AstraZeneca
Phase 3
1,407
Gdynia, Lodz, Szczecin, Warsaw
2019-01-04
Active, closed
Celgene
Phase 3
363
Lodz, Gdansk, Lubin, Poznan, Rzwszow, Słupsk, Wałbrzych, Wroclaw
2019-01-02
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Bydgoszcz, Gdansk, Glogow Wielkopolski, Katowice, Kielce, Lodz, Poznan, Rzeszów
2018-12-28
Active, closed
AstraZeneca
Phase 1
175
Bialystok, Bydgoszcz, Gdansk, Grudziądz, Lodz, Olsztyn, Tomaszów Mazowiecki, Warsaw
2018-12-27
Active, closed
AstraZeneca
Phase 2
401
Bialystok, Lodz, Poznan, Prabuty
2018-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
714
Krakow, Warsaw, Gdynia, Gliwice, Lodz
2018-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Warsaw, Bialystok, Gdynia, Gliwice, Grudziądz, Krakow, Lodz, Lublin
2018-12-07
Active, closed
OBI Pharma, Inc
Phase 3
575
Gdansk, Krakow, Lodz, Warsaw
2018-12-05
Active, closed
AbbVie
Phase 2
270
Poznan, Warsaw, Przemyśl, Szczecin, Lodz
2018-10-10
Recruiting
AMAG Pharmaceuticals, Inc.
Phase 3
129
Bialystok, Krakow, Lodz
2018-08-13
Active, closed
Janssen Research & Development, LLC
Phase 3
120
Lodz, Warsaw, Wroclaw
2018-07-11
Active, closed
Hoffmann-La Roche
Phase 3
927
Bialystok, Krakow, Lodz, Późna, Rzeszów, Warsaw, Zabrze
2018-05-28
Active, closed
Biotronik SE & Co. KG
Observational
3,030
Lodz, Poznan, Warsaw
2018-05-14
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Poznan, Bydgoszcz, Bystra, Wroclaw, Prabuty, Lodz
2018-04-24
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Chorzów, Lodz, Lublin, Słupsk, Warsaw
2018-04-17
Active, closed
Janssen Research & Development, LLC
Phase 1/2
125
Konin, Lodz, Warsaw
2018-04-05
Active, closed
AstraZeneca
Phase 2
273
Dąbrowa Górnicza, Gdansk, Gdynia, Grzepnica, Krakow, Lodz, Olsztyn, Poznan
2018-03-07
Active, closed
Acerta Pharma BV
Phase 1
12
Krakow, Lodz
2018-01-31
Active, closed
Sanofi
Phase 3
475
Poznan, Lodz, Warsaw, Gdansk
2017-12-07
Active, closed
BeiGene
Phase 3
590
Brzozów, Chorzów, Gdansk, Gdynia, Gliwice, Krakow, Legnica, Lodz
2017-10-31
Active, closed
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
Checkpoint Therapeutics, Inc.
Phase 1
272
Krakow, Lodz, Lublin, Poznan, Warsaw
2017-09-20
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Bialystok, Gdansk, Katowice, Krakow, Lodz, Lublin, Nowy Sącz, Rzeszów
2017-06-26
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
DrugIbrutinib
Pharmacyclics Switzerland GmbH
Phase 4
297
Brzozów, Gdansk, Chorzów, Lodz
2017-05-22
Active, closed
Acerta Pharma BV
Phase 3
635
Chorzów, Krakow, Lodz, Lublin, Olsztyn, Warsaw, Woj. Podkarpackie, Wroclaw
2017-04-05
Active, closed
Acerta Pharma BV
Phase 3
310
Bialystok, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Woj. Podkarpackie
2017-02-02
Active, closed
Acerta Pharma BV
Phase 1
72
Krakow, Lodz, Olsztyn, Warsaw
2016-04-20
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Bialystok, Bydgoszcz, Krakow, Kutno, Lodz, Lublin, Siedlce, Sochaczew
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Bialystok, Bydgoszcz, Gdynia, Gliwice, Kielce, Lodz, Olsztyn, Poznan
2015-11-19
Active, closed
AstraZeneca
Phase 3
953
Bydgoszcz, Kielce, Krakow, Lodz, Mrozy, Olsztyn, Poznan, Warsaw
2015-11-03
Active, closed
AstraZeneca
Phase 3
682
Krakow, Lodz, Otwock, Poznan, Racibórz, Warsaw, Wieliszew
2015-10-21
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Gdansk, Lodz, Opole, Warsaw
2015-08
Active, closed
Acerta Pharma BV
Phase 3
533
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Olsztyn, Opole, Słupsk
2015-07-28
Active, closed
Acerta Pharma BV
Phase 3
535
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Opole
2015-06-26
Active, closed
Acerta Pharma BV
Phase 2
124
Krakow, Lodz, Olsztyn
2015-03-02
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Lodz, Warsaw
2015-01-20
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Wroclaw, Gdynia, Krakow, Legnica, Lodz, Lublin, Olsztyn, Warsaw
2014-11
Active, closed
Eli Lilly and Company
Phase 3
453
Gdansk, Lodz, Olsztyn, Radom, Szczecin
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Gdansk, Bialystok, Lodz
2014-07-22
Active, closed
AstraZeneca
Phase 3
1,837
Gdansk, Grzepnica, Lodz, Olsztyn, Poznan, Warsaw
2014-04-22
Recruiting
Western Sydney Local Health District
Not applicable
1,058
Lodz, Warsaw
2014-02-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,207
Bialystok, Bydgoszcz, Gdansk, Kutno, Lodz, Poznan, Szczecin, Torun
2013-10-14
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Lodz, Lublin, Poznan, Wroclaw
2013-07-26
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Lodz
2013-03-18
By invitation
Texas Scottish Rite Hospital for Children
Observational
1,500
Lodz
2012-08
Active, closed
AstraZeneca
Phase 3
736
Bialystok, Lodz, Poznan
2005-02-13
By invitation
Copenhagen University Hospital, Rigshospitalet
Observational
23,000
Bialystok, Chorzów, Gdansk, Lodz, Poznan, Szczecin, Warsaw, Wroclaw
1994-01
Rows per page Showing 501–619 of 619
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/lodz?page=2

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 619 of those studies with a site in Lodz.

How many clinical trials are recruiting in Lodz?

278 of the 619 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 4 have not yet opened recruitment, 324 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.